Financing ·
On September 9, 2026, Teva Pharmaceutical Finance Netherlands II B.V., III B.V., and IV B.V. entered into an…
TEVJFTeva Pharmaceutical Industries Ltd
On September 9, 2026, Teva Pharmaceutical Finance Netherlands II B.V., III B.V., and IV B.V. entered into an underwriting agreement to sell approximately $4.9 billion in aggregate principal amount of senior notes, with Teva acting as guarantor. The offering includes €1.5 billion in Euro-denominated notes maturing in 2033 (4.250%) and 2036 (4.625%), and $3.2 billion in USD-denominated notes maturing in 2032 (5.250%), 2034 (5.500%), and 2037 (5.750%). Settlement is expected on September 16, 2026. Teva intends to use the net proceeds to fund conditional redemptions of existing notes, including all outstanding 6.750% Senior Notes due 2028, 7.875% and 7.375% Sustainability-Linked Senior Notes due 2029, up to $450 million in 4.750% notes due 2027, and up to €1.15 billion in 4.375% notes due 2030. Teva Pharmaceutical Industries Limited is a global leader in the generic pharmaceuticals industry.